anti-CD20 CAR NK-cell therapy (Celularity)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD20 CAR NK-cell therapy (Celularity)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesCelularity Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCelularity Inc

Active IndicationsN/A

Inactive IndicationsGlioblastoma

Other Information

ATC CodeN/A